NSCLC (NON-SMALL CELL LUNG CARCINOMA)
Clinical trials for NSCLC (NON-SMALL CELL LUNG CARCINOMA) explained in plain language.
Never miss a new study
Get alerted when new NSCLC (NON-SMALL CELL LUNG CARCINOMA) trials appear
Sign up with your email to follow new studies for NSCLC (NON-SMALL CELL LUNG CARCINOMA), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New lung cancer pill takes on chemo in major trial
Disease control Recruiting nowThis Phase 3 trial is testing a new oral drug called daraxonrasib (RMC-6236) against the standard chemotherapy docetaxel in about 590 people with advanced non-small cell lung cancer that has a specific RAS mutation. Participants must have already tried at least one prior treatmen…
Matched conditions: NSCLC (NON-SMALL CELL LUNG CARCINOMA)
Phase: PHASE3 • Sponsor: Revolution Medicines, Inc. • Aim: Disease control
Last updated Aug 08, 2026 00:03 UTC
-
New combo therapy targets rare lung cancer mutation
Disease control Recruiting nowThis study tests a new drug (firmonertinib) combined with radiation therapy for people with a specific type of stage III lung cancer that cannot be removed by surgery. The cancer must have a rare change in the EGFR gene. The goal is to see if the combination can delay cancer grow…
Matched conditions: NSCLC (NON-SMALL CELL LUNG CARCINOMA)
Phase: PHASE2 • Sponsor: Hunan Cancer Hospital • Aim: Disease control
Last updated Jul 10, 2026 00:00 UTC